Kodiak Sciences Inc. (KOD)


-0.28 (-5.34%)
Symbol KOD
Price $4.96
Beta 1.790
Volume Avg. 0.27M
Market Cap 259.454M
Shares () -
52 Week Range 4.9-12.8
1y Target Est -
DCF Unlevered KOD DCF ->
DCF Levered KOD LDCF ->
ROE -49.34% Strong Sell
ROA -38.69% Strong Sell
Operating Margin -
Debt / Equity 50.98% Buy
P/E -0.73
P/B 0.54 Buy


Consensus EPS

Upgrades & Downgrades

Latest KOD news

Dr. Victor Perlroth M.D.
NASDAQ Global Market

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.